Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secretrol for EMR Ulcer Management in Esophageal Adenocarcinoma
NCT02210494Phase 1Unknown
- Sponsor
- Effexus Pharmaceutical
- Start
- Apr 2013
- Primary completion
- Aug 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of secretin in Peptic ulcer disease (PUD), sponsored by Effexus Pharmaceutical. Primary endpoint: Adverse Events at 60 days. Status: unknown.
02
Drugs
secretin
03
Conditions
Peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02210494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210494.